Our Therapy Areas

Unlocking the power of what science can do

Home / Our Therapy Areas

Jump to section:

Harnessing Science to Create Novel Therapies

 

As the burden of disease grows and the population ages, we believe that science is the key to helping unlock the answers to healthcare challenges.

We’re adding value to patients by harnessing science, improving our understanding of disease biology and uncovering novel drivers for the diseases we aim to treat.

Our focus is on the following: Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Diseases.

Oncology

We are pushing the boundaries of science to bring about a remarkable change in the field of Oncology and transform the lives of patients living with cancer.
Learn more

BioPharmaceuticals

Our unwavering commitment lies in transforming care for billions of people living with chronic diseases and deliver long-lasting immunity.
Learn more

Rare Disease

Our mission is to transform the lives of people affected by rare diseases and devastating conditions. By understanding patients’ unique needs, we can research and develop innovative medicines, support access, and advocate for the rare disease community.
Learn more

Our Medicines

 

The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered.

We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus is on the following: Cardiovascular, Renal and Metabolism, Oncology, Respiratory

Adverse Events Reporting

 

All pharmacologically effective drugs have benefits and risks. The risk may be insignificant or may be acceptable in relation to the drug's therapeutic action. Continuous monitoring of the safety of a drug throughout the duration of its use helps to ensure that its risks and benefits remain acceptable. AstraZeneca is committed to protecting the safety of patients who receive our products.

Click here for full information

Latest Updates

AstraZeneca Pharma India maintains growth momentum with a strong start to FY2026–27, driven by the strength of our portfolio
AstraZeneca Pharma India receives CDSCO approval for Trastuzumab Deruxtecan for adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment
AstraZeneca Pharma India receives CDSCO approval for trastuzumab deruxtecan followed by taxane, trastuzumab, and pertuzumab (THP) for adults with HER2-positive Stage II or III early breast cancer
All press releases

Patient’s Corner

We always strive to remain patient-centric in line with our values of

We Put Patients First.’

Approval ID: IN-15293 | Approved Date: 06/11/2024 | Expiration Date: 29/10/2026